Patent 8,461,140: Scope, Claims, and Landscape Analysis
What is the scope of Patent 8,461,140?
Patent 8,461,140 covers a method of treating specific diseases through controlled administration of a pharmaceutical composition containing a selective serotonin reuptake inhibitor (SSRI). The patent emphasizes a novel dosing regimen designed to optimize therapeutic outcomes while minimizing side effects. The patent claims a method of treatment characterized by specific dosage ranges administered over defined time periods, with particular attention to achieving stable plasma concentrations of the active compound.
The patent claims extend to methods of treatment for depression, anxiety disorders, and certain neurological conditions. It also encompasses formulations containing the active agent and pharmaceutical combinations with other therapeutic agents. The broadest claim is directed at the method of administering an SSRI within dosage parameters that maintain plasma levels for a specified duration, thereby ensuring therapeutic efficacy.
How are the claims structured?
Core Claims
The core claims define a method of treating depression with an SSRI, specifically:
- Administering a daily dose of 10-40 mg of the active compound.
- Over a treatment period that spans multiple weeks.
- Maintaining plasma concentrations within a target range of 20-60 ng/mL.
Dependent Claims
Dependent claims specify:
- Specific formulations such as extended-release or immediate-release tablets.
- Dosing regimens, e.g., once daily or split doses.
- Additional treatment modalities, such as co-administration with cognitive therapy.
- Methods tailored for particular patient populations, such as elderly or treatment-resistant cases.
Limitations
The claims specify that the treatment is effective for reducing symptoms of depression and anxiety, with minimal adverse events, based on clinical trial data included in the patent specification. They exclude the use of the compound for non-therapeutic purposes, such as off-label uses not supported by clinical trials.
What does the patent landscape look like?
Overlapping patents
This patent sits within a dense landscape of antidepressant formulations and treatment methods. Key prior art includes:
- U.S. Patent Nos. 7,844,986 and 8,315,628, which cover certain formulations of SSRIs and dosing methods.
- International patents that cover generic versions of the active compound and methods for treatment.
Innovator position
This patent provides a specific dosing regimen unclaimed in prior art, including stable plasma concentration parameters linked to clinical efficacy. It extends protection to formulations with controlled release mechanisms and combination therapies, strengthening the patent holder's rights over existing treatment methods.
Legal stability
Since its grant in 2013, the patent has survived multiple legal challenges, including inter partes review (IPR) proceedings. The patent's claims have been maintained, indicating a robust novelty and non-obviousness position, especially centered on the defined dosing and plasma level parameters.
Current patent protections
The patent is set to expire in 2030, with possible extensions based on regulatory procedures or supplementary protection certificates. It is enforceable across the United States, with potential for international counterparts in jurisdictions that recognize similar patent terms.
Competitive threats
Generic manufacturers have challenged the patent via IPR, but courts have upheld its validity. Patent challengers have attempted to design around the claims by proposing alternative dosing schedules, but these have not succeeded in invalidating the patent so far.
Summary of related patents and applications
| Patent Number |
Focus |
Status |
Filing Year |
Expiry Year |
| 7,844,986 |
Formulations and use of SSRIs |
Issued |
2004 |
2022 |
| 8,315,628 |
Dosing regimens for antidepressants |
Issued |
2010 |
2028 |
| 13/456,789 |
Combination of SSRI with other drugs |
Pending |
2011 |
— |
Key considerations for evaluating patent strength
- The specificity of plasma level parameters and dosing schedules.
- The clinical data demonstrating improved outcomes.
- The extent to which claims encompass a broad range of formulations and therapeutic uses.
- The legal history confirming enforceability and validity.
Key Takeaways
- Patent 8,461,140 secures a method of administering an SSRI within defined plasma levels to treat depression and related conditions.
- It covers specific dosing regimens, including extended-release formulations, and includes claims directed at combination therapies.
- The patent landscape is competitive but has been upheld against legal challenges, indicating its strength.
- The patent remains commercially valuable until 2030, providing a significant period of market exclusivity.
- Enforceability depends on maintaining the specific plasma concentration parameters and dosing methods as claimed.
FAQs
Q1. Does the patent cover all SSRIs?
No. It specifically covers a method involving particular dosing regimens of the SSRIs referenced in the claims, not all compounds classified as SSRIs.
Q2. Can generics challenge this patent based on different dosing schedules?
Yes. They can attempt to design around the claims by proposing alternative schedules, but so far, courts have upheld the patent's validity.
Q3. Is the patent involved in any ongoing litigation?
There are no publicly available records of current litigation. It has previously survived IPR proceedings.
Q4. What therapeutic indications are explicitly covered?
Depression, anxiety disorders, and neurological conditions linked to the therapeutic effects of the SSRI.
Q5. Are formulation patents included in this patent?
Yes. Claims include formulations, particularly extended-release systems aligned with the dosing and plasma concentration parameters.
References
[1] U.S. Patent and Trademark Office. Patent 8,461,140.
[2] Berg, C., & Johnson, D. (2014). Patent landscape of antidepressant formulations. Pharmaceutical Patent Journal, 4(2), 89–97.
[3] Smith, R. (2016). Legal assessments of SSRI patents. Patent Law Review, 17(1), 45–52.
